Home・Stock List・Novartis AG

Novartis AG

Closed

152.16 -0.99

Buy Sell

Overview

Share price change

24h

Current

Min

151.62

Max

153.72

Key metrics
By Trading Economics
Income	110M 3.3B
Sales	894M 14B
P/E Sector Avg	23.979 57.366
EPS	2.41
Dividend yield	2.98
Profit margin	22.654
Employees	75,267
EBITDA	526M 5.9B

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+3.37% upside

Dividends
By Acuity
Dividend yield Sector Avg	2.98% 2.16%

Market Stats
By TradingEconomics
Market Cap	15B 300B
Previous open	153.15
Previous close	152.16

Novartis AG Chart

Past performance is not a reliable indicator of future results.

Related News

30 Aug 2026, 23:53 UTC

EUR/AUD is trading slightly higher in after-market hours, continuing its performance since Friday's close, though it remains near the lower end of its one-month range.

30 Aug 2026, 23:53 UTC

Correlated Moves

Gold/AUD is lower amid cautious sentiment following Barclays' warning of a potential commodity shock due to adverse weather and underinvestment in production.

30 Aug 2026, 23:53 UTC

Correlated Moves

Silver Ounce vs Euro is trading lower amid a broader decline in gold prices. Market sentiment is impacted by a Barclays report on potential commodity shocks.

30 Aug 2026, 23:51 UTC

Correlated Moves

The S&P 500 Index is lower amid broader market trends and cautious investor sentiment following Barclays' forecasts of a potential commodity shock.

30 Aug 2026, 23:51 UTC

Ethereum Drops 2.5% Amid Tech Stock Sell-Off and Economic Indicators, While Commodity Shock Looms from El Niño and Geopolitical Tensions Persist.

30 Aug 2026, 23:51 UTC

Cryptocurrency Markets Decline Amid Geopolitical Tensions and Commodity Shock Warnings, with Key Economic Data Releases Ahead.

30 Aug 2026, 23:51 UTC

Cryptocurrency markets decline as hedge funds sell tech stocks, while looming commodity shocks and geopolitical tensions raise inflation concerns ahead of key U.S. and Canadian labor data releases.

30 Aug 2026, 23:51 UTC

Cryptocurrency markets decline as hedge funds sell tech stocks; Japan's economic indicators reveal consumer spending trends amid global uncertainties, while Barclays warns of a commodity shock from El Niño.

30 Aug 2026, 23:51 UTC

Brazil's S&P Global Services PMI set for release on September 3, with analysts wary of further contraction following August's drop to 49.7 amid rising costs and political uncertainties.

30 Aug 2026, 23:51 UTC

Australia's Building Permits Expected to Decline by 4.8% in July Amidst Economic Pressures and Market Volatility

30 Aug 2026, 23:51 UTC

EUR/DKK remains effectively unchanged in after-market trading, showing unusual stability within a narrow band around its one-month trading range midpoint.

30 Aug 2026, 23:51 UTC

Correlated Moves

Gold Ounce vs Euro is trading lower, continuing a five-session decline, influenced by falling Silver and cautious sentiment amid forecasts of a commodity shock.

30 Aug 2026, 23:51 UTC

News

Bitcoin is trading lower today, despite earlier gains and social media discussions about Steak 'n Shake's Bitcoin initiative and potential AI investor interest.

30 Aug 2026, 23:51 UTC

Bitcoin is trading lower during Sunday’s session amid heightened volatility. The price remains above its 20-day moving average and near its one-month range.

30 Aug 2026, 23:42 UTC

Correlated Moves

The Nasdaq 100 Index is lower during Sunday’s session, reflecting broader market caution amid concerns over potential commodity shocks and adverse weather patterns.

30 Aug 2026, 23:41 UTC

Japan's Industrial Production Expected to Decline in July Amid Global Economic Concerns and Commodity Supply Chain Disruptions.

30 Aug 2026, 23:41 UTC

U.S. Unemployment Rate Release on September 4, 2026 Expected at 4.2%, Amid Cautious Optimism and Potential Fed Policy Implications

30 Aug 2026, 23:41 UTC

US Average Hourly Earnings Expected to Rise 0.2% Amid Cautious Market Sentiment on Wage Growth and Inflation Concerns

30 Aug 2026, 23:41 UTC

Labor Force Participation Rate in the U.S. Declines to 61.4%, Raising Concerns Ahead of September 2026 Data Release

30 Aug 2026, 23:41 UTC

Investors Anticipate Key U.S. Average Hourly Earnings Data Amid Rising Inflation Concerns Ahead of September 4 Release

30 Aug 2026, 23:41 UTC

US Non-Farm Payrolls Expected to Rise by Only 45K Jobs in August Amid Growing Employment Concerns

30 Aug 2026, 23:41 UTC

Canada's Unemployment Rate Expected to Decrease Slightly to 6.4% Amidst Economic Challenges and Improved Employment Figures

30 Aug 2026, 23:41 UTC

Canada's Labor Force Participation Rate Release on September 4, 2026, May Reflect Employment Dynamics Amid Housing Initiatives.

30 Aug 2026, 23:41 UTC

Canada's Employment Change Forecast for August 2026 Predicts +15.8K Jobs Amid Positive Labor Market Sentiment Following July's Surprising Gain of +75.1K Positions

30 Aug 2026, 23:41 UTC

Canada's Full-Time Employment Change Report Set for Release on September 4, Amid Economic Concerns and Political Developments.

30 Aug 2026, 23:41 UTC

Canada's Part-Time Employment Change Report Set for September 4, 2026, Amid Cautious Optimism in Labor Market Dynamics.

30 Aug 2026, 23:31 UTC

Correlated Moves

Avalanche is trading lower amid broader market sentiment, reflecting volatility. The asset remains above its 20-day moving average despite today's decline.

30 Aug 2026, 23:31 UTC

Terra is trading lower today amid ongoing volatility and remains below its 20-day moving average, reflecting a decline since Saturday's session.

30 Aug 2026, 23:31 UTC

Japan's Retail Sales Expected to Rise 0.03% YoY in July Amid Cautious Economic Sentiment and Weak Bond Market Performance

30 Aug 2026, 23:31 UTC

Correlated Moves

XRP is declining during Sunday’s session amid notable volatility, aligning with a drop in Bitcoin. The asset remains above its 20-day moving average.

Peer Comparison

Price change

Novartis AG Forecast

Price Target

By TipRanks

3.37% upside

12 Months Forecast

Average 159 USD 3.37%

High 180 USD

Low 139 USD

Based on 5 Wall Street analysts offering 12 month price targets forNovartis AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Novartis AG - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.